The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was $27.3 for the day, down -2.53% from the previous closing price of $28.01. In other words, the price has decreased by -$2.53 from its previous closing price. On the day, 2.32 million shares were traded. RARE stock price reached its highest trading level at $28.2142 during the session, while it also had its lowest trading level at $27.11.
Ratios:
Our analysis of RARE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 6.17 whereas as Long-Term Debt/Eq ratio is at 5.70.
On June 06, 2024, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $56 to $67.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.RBC Capital Mkts initiated its Outperform rating on April 22, 2024, with a $77 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 20 ’25 when Sanders Corazon (Corsee) D. sold 2,405 shares for $37.39 per share. The transaction valued at 89,923 led to the insider holds 15,344 shares of the business.
CORAZON D. SANDERS bought 2,405 shares of RARE for $89,923 on Jun 20 ’25. On May 05 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 520 shares for $39.24 each. As a result, the insider received 20,405 and left with 71,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2580996608 and an Enterprise Value of 2978820608. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.37 while its Price-to-Book (P/B) ratio in mrq is 17.74. Its current Enterprise Value per Revenue stands at 5.043 whereas that against EBITDA is -6.233.
Stock Price History:
The Beta on a monthly basis for RARE is 0.24, which has changed by -0.39144003 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -21.69%, while the 200-Day Moving Average is calculated to be -34.08%.
Shares Statistics:
RARE traded an average of 1.66M shares per day over the past three months and 3591340 shares per day over the past ten days. A total of 93.74M shares are outstanding, with a floating share count of 88.38M. Insiders hold about 6.52% of the company’s shares, while institutions hold 96.28% stake in the company. Shares short for RARE as of 1751241600 were 6820252 with a Short Ratio of 4.12, compared to 1748563200 on 5546745. Therefore, it implies a Short% of Shares Outstanding of 6820252 and a Short% of Float of 7.470000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
